Overview

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effects of daratumumab and lenalidomide without steroids for treating patients with multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Rochester
Treatments:
Daratumumab
Dexamethasone
Lenalidomide